Rana R. McKay, MD, on Mutated Prostate Cancer, PARP Inhibition, and Radical Prostatectomy

January 02, 2024 By The ASCO Post Staff

Rana R. McKay, MD, of the University of California, San Diego, discusses phase II findings from the Neptune study of neoadjuvant olaparib plus androgen-deprivation therapy followed by radical prostatectomy in patients with intermediate-risk or high-risk prostate cancer marked by germline or somatic BRCA1/2 gene alterations. This population generally has inferior outcomes, and PARP inhibition has shown efficacy in these patients.

Related Content